Transforming growth factor-β is required for vasculogenic mimicry formation in glioma cell line U251MG

Cancer Biology and Therapy

Volumn 12, Issue 11, 2011, Pages 978-988

  Ling, Gengqiang ^a,b   Wang, Shiyong ^a,b   Song, Zhenhua ^a,b   Sun, Xinlin ^a,b   Liu, Yijing ^a,b   Jiang, Xiaodan ^a,b   Cai, Yingqian ^a,b   Du, Mouxuan ^a,b   Ke, Yiquan ^a,b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Glioma; Matrix metalloproteinase; Short hairpin RNA; Transforming growth factor ; Vasculogenic mimicry

Indexed keywords

EPHRIN RECEPTOR A2; GELATINASE A; GELATINASE B; LAMININ; LAMININ 5GAMMA2 CHAIN; MATRIX METALLOPROTEINASE 14; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN;

ARTICLE; CARCINOGENESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; GENETIC TRANSCRIPTION; GLIOMA; HUMAN; HUMAN CELL; NEOVASCULARIZATION (PATHOLOGY); NEUROPATHOLOGY; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL LINE; VASCULOGENIC MIMICRY; ZYMOGRAPHY;

CELL LINE, TUMOR; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GLIOMA; HUMANS; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASES; NEOVASCULARIZATION, PATHOLOGIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 82755167782     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.12.11.18155     Document Type: Article

References (48)

1. Central Brain Tumor Registry of the United States: Statistical Report: Primary Brian Tumors in the United States, 1998-2002. Published by Central Brain Tumor Registry of the United States, 2005.
2. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci 2007; 8:610-22; PMID:17643088; http://dx.doi.org/10.1038/nrn2175
3. Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, Dowell JM, Reardon DA, Quinn JA, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007; 13:1253-9; PMID: 17317837; http://dx.doi.org/10.1158/1078-0432. CCR-06-2309
4. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009; 27:740- 5; PMID:19114704; http://dx.doi.org/10.1200/JCO.2008.16.3055
5. Bergers G, Hanahan D. Modes of resistance to antiangiogenic therapy. Nat Rev Cancer 2008; 8:592-603; PMID:18650835; http://dx.doi.org/10.1038/nrc2442
6. Kerbel RS, Yu J, Tran J, Man S, Viloria-Petit A, Klement G, et al. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev 2001; 20:79-86; PMID:11831651; http://dx.doi.org/10.1023/A:1013172910858
7. Miller KD, Sweeney CJ, Sledge GW, Jr. Can tumor angiogenesis be inhibited without resistance? EXS 2005; 94:95-112; PMID:15617473; http://dx.doi.org/10. 1007/3-7643-7311-3-7
8. Pàez-Ribes M,Allen E,Hudock J, Takeda T,Okuyama H, Vinals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15:220-31; PMID: 19249680; http://dx.doi.org/10.1016/j.ccr.2009.01.027
9. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15:232-9; PMID: 19249681; http://dx.doi.org/10.1016/j.ccr.2009.01.021
10. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LMG, Pe'er J, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999; 155:739-52; PMID: 10487832; http://dx.doi.org/10.1016/S0002-9440(10) 65173-5
11. Shirakawa K, Tsuda H, Heike Y, Kato K, Asada R, Inomata M, et al. Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res 2001; 61:445-51; PMID:11212228
12. Sood AK, Seftor EA, Fletcher MS, Gardner LM, Heidger PM, Buller RE, et al. Molecular determinants of ovarian cancer plasticity. Am J Pathol 2001; 158:1279-88; PMID:11290546; http://dx.doi.org/10.1016/S0002-9440(10)64079-5
13. Sood AK, Fletcher MS, Zahn CM, Gruman LM, Coffin JE, Seftor EA, et al. The clinical significance of tumor cell-lined vasculature in ovarian carcinoma: implications for anti-vasculogenic therapy. Cancer Biol Ther 2002; 1:661-4; PMID:12642690
14. Sharma N, Seftor RE, Seftor EA, Gruman LM, Heidger PM, Jr., Cohen MB, et al. Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: role in vasculogenic mimicry. Prostate 2002; 50:189-201; PMID:11813211; http://dx.doi.org/10.1002/pros.10048
15. Passalidou E, Trivella M, Singh N, Ferguson M, Hu J, Cesario A, et al. Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas. Br J Cancer 2002; 86:244-9; PMID:11870514; http://dx.doi.org/10. 1038/sj.bjc.6600015
16. Vartanian AA, Stepanova EV, Gutorov SL, Solomko E, Grigorieva IN, Sokolova IN, et al. Prognostic significance of periodic acid-Schiff-positive patterns in clear cell renal cell carcinoma. Can J Urol 2009; 16:4726-32; PMID:19671223
17. van der Schaft DW, Hillen F, Pauwels P, Kirschmann DA, Castermans K, Egbrink MG, et al. Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Res 2005; 65:11520-8; PMID:16357161; http://dx.doi.org/10.1158/0008-5472.CAN-05-2468
18. Yue WY, Chen ZP. Does vasculogenic mimicry exist in astrocytoma? J Histochem Cytochem 2005; 53:997-1002; PMID:15923371; http://dx.doi.org/10.1369/ jhc.4A6521.2005
19. El Hallani S, Boisselier B, Peglion F, Rousseau A, Colin C, Idbaih A, et al. A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain 2010; 133:973-82; PMID:20375132; http://dx.doi.org/10.1093/brain/awq044
20. van der Schaft DW, Seftor RE, Seftor EA, Hess AR, Gruman LM, Kirschmann DA, et al. Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J Natl Cancer Inst 2004; 96:1473-7; PMID:15467037; http://dx.doi.org/10.1093/jnci/djh267
21. Folberg R, Maniotis AJ. Vasculogenic mimicry. APMIS 2004; 112:508-25; PMID:15563313; http://dx.doi.org/10.1111/j.1600-0463.2004.apm11207-0810.x
22. Sun B, Zhang S, Zhao X, Zhang W, Hao X. Vasculogenic mimicry is associated with poor survival in patients with mesothelial sarcomas and alveolar rhabdomyosarcomas. Int J Oncol 2004; 25:1609-14; PMID:15547697
23. Shirakawa K, Heike Y, Watanabe I, Yamada S, Saito K, Konishi F. Vasculogenic mimicry and pseudo-comedo formation in breast cancer. Int J Cancer 2002; 99: 821-8; PMID:12115483; http://dx.doi.org/10.1002/ijc.10423
24. Hess AR, Seftor EA, Seftor RE, Hendrix MJ. Phosphoinositide 3-kinase regulates membrane Type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry. Cancer Res 2003; 63:4757-62; PMID:12941789
25. Kjellman C, Olofsson SP, Hansson O, Von Schantz T, Lindvall M, Nilsson I, et al. Expression of TGF-β isoforms, TGF-β receptors, and SMAD molecules at different stages of human glioma. Int J Cancer 2000; 89:251-8; PMID:10861501; http://dx.doi.org/10.1002/1097-0215(20000520)89:3〈251::AID- IJC7〉3.0.CO;2-5
26. Yamada N, Kato M, Yamashita H, Nister M, Miyazono K, Helden CH, et al. Enhanced expression of transforming growth factor-beta and its type-I and type-II receptors in human glioblastoma. Int J Cancer 1995; 62:386-92; PMID:7635563; http://dx.doi.org/10.1002/ijc.2910620405
27. Nawshad A, Lagamba D, Polad A, Hay ED. Transforming growth factor-beta signaling during epithelial-mesenchymal transformation: implications for embryogenesis and tumor metastasis. Cells Tissues Organs 2005; 179:11-23; PMID:15942189; http://dx.doi.org/10.1159/000084505
28. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2:442-54; PMID:12189386; http://dx.doi.org/10.1038/nrc822
29. Sun T, Zhao N, Zhao X, Gu Q, Zhang S, Che N, et al. Expression and functional significance of Twist1 in hepatocellular carcinoma: Its role in vasculogenic mimicry. Hepatology 2010; 51:545-56; PMID:19957372
30. Schatton T, Frank MH. Cancer stem cells and human malignant melanoma. Pigment Cell Melanoma Res 2008; 21:39-55; PMID:18353142; http://dx.doi.org/10. 1111/j.1755-148X.2007.00427.x
31. Hendrix MJ, Seftor EA, Meltzer PS, Gardner LM, Hess AR, Kirschmann DA, et al. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci USA 2001; 98:8018-23; PMID: 11416160; http://dx.doi.org/10.1073/pnas.131209798
32. Hess AR, Seftor EA, Gruman LM, Kinch MS, Seftor RE, Hendrix MJ. VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry. Cancer Biol Ther 2006; 5:228-33; PMID:16481735; http://dx.doi.org/10.4161/cbt.5.2.2510
33. Hess AR, Seftor EA, Gardner LM, Carles-Kinch K, Schneider GB, Seftor RE, et al. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res 2001; 61:3250-5; PMID:11309274
34. Seftor RE, Seftor EA, Koshikawa N, Meltzer PS, Gardner LM, Bilban M, et al. Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase- 2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res 2001; 61:6322-7; PMID:11522618
35. Paulis YW, Soetekouw PM, Verheul HM, Tjan-Heijnen VC, Griffioen AW. Signalling pathways in vasculogenic mimicry. Biochim Biophys Acta 2010; 1806:18-28.
36. Kim ES, Kim MS, Moon A. TGF-beta-induced upregulation ofMMP-2 andMMP-9 depends on p38MAPK, but not ERK signaling in MCF10A human breast epithelial cells. Int J Oncol 2004; 25:1375-82; PMID:15492828
37. Kim ES, Sohn YW, Moon A. TGF-beta-induced transcriptional activation of MMP-2 is mediated by activating transcription factor (ATF)2 in human breast epithelial cells. Cancer Lett 2007; 252:147-56; PMID: 17258390; http://dx.doi.org/10.1016/j.canlet.2006.12.016
38. Kuo YC, Su C, Liu C, Chen T, Chen C, Wang T. Transforming growth factor-beta induces CD44 cleavage that promotes migration of MDA-MB-435s cells through the up-regulation of membrane type1-matrix metalloproteinase. Int J Cancer 2009; 124:2568-76; PMID:19243022; http://dx.doi.org/10.1002/ijc.24263
39. Tobar N, Villar V, Santibanez JF. ROS-NF kappa Beta mediates TGF-beta1-induced expression of urokinasetype plasminogen activator, matrix metalloproteinase-9 and cell invasion. Mol Cell Biochem 2010; 340:195- 202; PMID:20204677; http://dx.doi.org/10.1007/s11010-010-0418-5
40. Wesolowska A, Kwiatkowska A, Slomnicki L, Dembinski M, Master A, Sliwa M, et al. Microglia-derived TGF-beta as an important regulator of glioblastoma invasion-an inhibition of TGF-beta-dependent effects by shRNA against human TGF-beta type II receptor. Oncogene 2008; 27:918-30; PMID:17684491; http://dx.doi.org/10.1038/sj.onc.1210683
41. Biswas S, Guix M, Rinehart C, Dugger TC, Chytil A, Moses HL, et al. Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Invest 2007; 117:1305-13; PMID:17415413; http://dx.doi.org/10.1172/JCI30740
42. Serwe A, Rudolph K, Anke T, Erkel G. Inhibition of TGF-beta signaling, vasculogenic mimicry and proinflammatory gene expression by isoxanthohumol. Invest New Drugs 2011. In press. PMID:21340508; http://dx.doi.org/10.1007/ s10637-011-9643-3PMID:21340508; DOI: 10.1007/s10637-011-9643-3.
43. Wu N, Zhao X, Liu M, Liu H, Yao W, Zhang Y, et al. Role of MicroRNA-26b in Glioma Development and Its Mediated Regulation on EphA2. PLoS ONE 2011; 6:e16264; PMID:21264258; http://dx.doi.org/10.1371/journal.pone.0016264
44. Zhang X, Guo SW, Wei CY. The effect of alphastatin peptide suppressing the hypoxia-induced vasculogenic mimicry formation of glioma. Journal of Medical Colleges of PLA 2010; 5:267-74.
45. Fillmore HL, VanMeter TE, Broaddus WC. Membrane type-matrix metalloproteinases (MT-MMPs): expression and function during glioma invasion. J Neurooncol 2001; 53:187-202; PMID:11716070; http://dx.doi.org/10.1023/A: 1012213604731
46. Zavadil J, Bottinger EP. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 2005; 24:5764-74; PMID:16123809; http://dx.doi.org/10. 1038/sj.onc.1208927
47. Bhowmick NA, Ghiassi M, Bakin A. Transforming growth factor-b1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell 2001; 12:27-36; PMID: 11160820
48. Lu C, Li XY, Hu YX, Rowe RG, Weiss SJ. MT1-MMP controls human mesenchymal stem cell trafficking and differentiation. Blood 2010; 115:221-9; PMID: 19901267; http://dx.doi.org/10.1182/blood-2009-06-228494